Incyclix Bio Secures $5M Series B Extension to Advance CDK2 Inhibitor INX-315 in Resistant Breast and Ovarian Cancers
核心洞察
Incyclix Bio (搜索) raised an additional $5 million in Series B funding from Hatteras Venture Partners (搜索) to advance INX-315, a selective CDK2 (搜索) inhibitor targeting advanced and metastatic cancers.
The funding supports the ongoing Phase 1/2 open-label trial (NCT05735080) focusing on CDK4/6 (搜索) inhibitor-resistant ER+/HER2- breast cancer and CCNE1 (搜索)-amplified solid tumors.
Hatteras Venture Partners (搜索) added board representation with Dr. Kseniya Simpson joining as director and Dr. Christy Shaffer as observer, indicating increased oversight during dose escalation and combination cohort phases.
Incyclix Bio (搜索) has secured an additional $5 million in Series B financing from new investor Hatteras Venture Partners (搜索) to advance development of INX-315, a selective CDK2 (搜索) inhibitor currently in Phase 1/2 clinical testing for advanced and metastatic breast and ovarian cancers. The funding comes with governance changes as Hatteras partner Kseniya Simpson, Ph.D., joins the company's board of directors and general partner Christy Shaffer, Ph.D., becomes a board observer.
Targeting CDK2 in Resistant Cancers
INX-315 is being evaluated in an ongoing Phase 1/2 open-label trial (NCT05735080) across recurrent advanced and metastatic cancers, with particular emphasis on breast and ovarian settings. The study focuses on patients with CDK4/6 (搜索) inhibitor-resistant ER+/HER2- breast cancer and CCNE1 (搜索)-amplified solid tumors, addressing resistance patterns that emerge after CDK4/6 inhibition and endocrine therapy in hormone receptor-positive breast cancer.
"We are encouraged by Hatteras's strong enthusiasm for our CDK2 (搜索) program and their support in advancing INX-315 toward meaningful clinical outcomes," said Patrick Roberts, Pharm.D., Ph.D., Chief Executive Officer and Co-Founder of Incyclix Bio (搜索). "Additionally, we're pleased to welcome Kseniya and Christy to our board and look forward to working with them during this pivotal time of growth for Incyclix."
Strategic Financing in Competitive Landscape
The targeted financing appears designed to bridge to near-term clinical catalysts rather than reset the balance sheet, supporting dose escalation, combination cohort initiation, and preparation for dose expansion. Hatteras joins other top-tier investors from the Series B round, including Boxer Capital, RA Capital Management, Eshelman Ventures, Eli Lilly and Company, Pharmacosmos and Cape Fear BioCapital.
"CDK2 (搜索) inhibition represents an exciting opportunity to address unmet need that remains in breast and ovarian cancer treatment," said Kseniya Simpson, Ph.D. "We believe in Incyclix's highly experienced team and their capabilities to bring a best-in-class treatment option to patients with advanced and resistant cancer."
Development Challenges and Opportunities
Competition around CDK2 (搜索) is intensifying, with multiple programs advancing through early clinical testing from larger pharmaceutical companies. Differentiation will depend on pharmacologic selectivity, a tolerability profile supporting chronic use, and combination flexibility with endocrine therapies, PARP inhibitors, or chemotherapy without compounding myelosuppression or drug-drug interaction liabilities.
Biomarker strategy will be critical for success. Companies in this space are focusing on cyclin E/CCNE1 (搜索) amplification and other signatures of CDK2 (搜索) dependency. Aligning companion diagnostics and practical screening workflows will determine how quickly programs can transition from broad dose-finding to signal-seeking in enriched patient cohorts.
Near-Term Milestones
Key upcoming catalysts include selection of the recommended Phase 2 dose, first combination cohort readouts, and formalization of biomarker cutoffs and companion diagnostic plans. The added board presence from Hatteras signals an execution-heavy phase focused on locking in combination strategies and sharpening biomarker plans to guide enrollment.
For the program to succeed, INX-315 must demonstrate activity that meaningfully re-sensitizes post-CDK4/6 (搜索) endocrine-resistant disease with manageable hematologic and gastrointestinal toxicity. Such results could justify expedited regulatory pathways in tightly defined subsets, including CCNE1 (搜索)-amplified ovarian cancer.
The company faces clear risks including target validation in humans, overlapping toxicity in combinations, recruitment challenges in a crowded hormone receptor-positive landscape, and the need to translate preclinical selectivity into clinically meaningful therapeutic windows. Competitive readouts from peer CDK2 (搜索) programs will establish benchmarks for response rates and tolerability that Incyclix must meet or exceed.